Claritev Corporation (CTEV) is a McLean, Virginia-based technology, data and insights company that helps healthcare payers, providers and third-party administrators control costs. Formerly known as MultiPlan, the company runs three businesses: claims intelligence and out-of-network cost containment, one of the largest independent PPO networks in the U.S., and payment and revenue integrity services processing billions of claims annually. On Thursday, the stock traded at $20.98, down 5.92% from Wednesday's close of $22.30, a decline of $1.32. The move lower came without any verified news or fundamental catalyst. Instead, it extended a steady slide that began after the shares peaked at $28.67 on Nov. 10.
No verified news or fundamental catalyst found explains Thursday's decline. There was no earnings release, guidance update, securities filing, analyst rating change, litigation development, or financing announcement tied to the move. The company's most recent material disclosure remains its third-quarter report on Nov. 9, which showed revenue of $268.3 million, up 9.1% year over year and ahead of consensus, with adjusted EBITDA of $162.0 million. That report drove gains of 5.68% on Nov. 9 and 19.46% on Nov. 10, and it is now more than a week old and fully absorbed.
The most data-supported explanation is a post-rally unwind. After touching $28.67, the stock has fallen in five of the last six sessions, including drops of 6.82% on Nov. 16, 8.16% on Nov. 17 and 2.83% on Nov. 18. That pattern is consistent with profit-taking and momentum-driven selling after a 38% six-session advance, rather than a response to new information. It is also consistent with the mechanics of a thinly traded small-cap: only about 6.8 million of 17.1 million shares are in public hands, so modest order imbalances can move the quote several percentage points. Selling pressure has been persistent but not panicked — turnover of roughly 211,000 and 313,000 shares on Nov. 17 and Nov. 18 compares with 731,000 and 933,000 shares on the two up-days, indicating thinning participation rather than heavy liquidation.
Even after the pullback, the equity is pricing a leveraged capital structure. The market capitalization of roughly $360 million sits against an enterprise value of about $5.1 billion, reflecting the debt taken on during the 2025 refinancing. That leverage explains the outsized reaction function: small changes in expectations about free cash flow or the No Surprises Act reimbursement environment translate into large percentage moves in the shares. The company has said it expects 2026 free cash flow to turn positive at the midpoint of its guidance and has made deleveraging a capital-allocation priority, but the heavy debt load keeps the equity sensitive.
Thursday's decline was company-specific rather than sector-driven. Broader healthcare services and payment-integrity peers did not fall by a comparable margin, and the major indices were not down materially, making this a divergent move. Technically, the shares are now roughly 17% below both their 50-day and 200-day moving averages, which are clustered near $25.35 and $25.40 — a level that has flipped from support into resistance. The relative strength index stood at 43 before Thursday's session, meaning the stock is approaching but has not reached oversold territory. Volume has been running below its 20-day average of about 324,000 shares on the down-days, a signature of drift rather than capitulation.
The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Claritev scores 11 out of 100.
Verified news strength is weak: nothing new was published Thursday, and the last material disclosure — a solid but in-line third-quarter report — has already been digested. The price move is also unexceptional by this stock's standards. At 5.92%, it is about 1.4 times the average absolute daily change of roughly 4.2% across the last 60-plus sessions, and moves of equal or greater size occurred 15 times in that window. Weak news plus an ordinary move for a volatile micro-cap produces a low score.
Attention now shifts to fourth-quarter and full-year 2026 results, expected in late February 2027, when management is likely to update progress against its preliminary 2027 revenue target and its free cash flow objective. Investors will focus on bookings momentum — the company has already booked more than $100 million in annual contract value year to date — and on whether the No Surprises Act dispute volume that lifted third-quarter results persists. On the risk side, customer concentration among large national payers, the weight of the debt stack, and the slow pace of new client additions outside the core payer segment all remain uncertainties. Regulatory rulings on out-of-network reimbursement could swing sentiment quickly in either direction.
Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions make it into the curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the list changes as market conditions evolve. Reviewing this page can help traders see which automated approaches are currently working — and consider how they might apply to names like CTEV.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CTEV saw its Momentum Indicator move below the 0 level on November 19, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 77 similar instances where the indicator turned negative. In 72 of the 77 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CTEV turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 41 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CTEV moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for CTEV moved below the 200-day moving average on November 18, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CTEV broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CTEV's RSI Oscillator exited the oversold zone, 26 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +26.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTEV advanced for three days, in 223 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.307) is normal, around the industry mean (4.523). P/E Ratio (-1.336) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.562) is also within normal values, averaging (6.105).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. CTEV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ServicestotheHealthIndustry